Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
08 Feb 2024
Historique:
received: 09 12 2023
pmc-release: 08 02 2025
medline: 14 2 2024
pubmed: 14 2 2024
entrez: 14 2 2024
Statut: epublish

Résumé

Provided herein are novel emopamil-binding protein (EBP) inhibitors, their pharmaceutical compositions, the use of such compounds in treating multiple sclerosis, and processes for preparing such compounds.

Identifiants

pubmed: 38352824
doi: 10.1021/acsmedchemlett.3c00555
pmc: PMC10860179
doi:

Types de publication

Editorial

Langues

eng

Pagination

163-164

Informations de copyright

Published 2024 by American Chemical Society.

Déclaration de conflit d'intérêts

The author declares no competing financial interest.

Auteurs

Ram W Sabnis (RW)

Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.

Classifications MeSH